![](/img/cover-not-exists.png)
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
Witzig, T. E., Tomblyn, M. B., Misleh, J. G., Kio, E. A., Sharkey, R. M., Wegener, W. A., Goldenberg, D. M.Volume:
99
Language:
english
Journal:
Haematologica
DOI:
10.3324/haematol.2014.112110
Date:
November, 2014
File:
PDF, 4.97 MB
english, 2014